We encountered a neonatal patient with hemophagocytic lymphohistiocytosis (HLH) whose mother was positive for anti-Ro/SSA and anti-La/SSB antibodies. Complete atrioventricular block was found in a male patient at 29 weeks of gestation. The patient was born at 40 weeks of gestation. He showed severe circulatory disturbance at 22 h after the birth, and he also had elevated serum levels of aspartate aminotransferase (1027 IU l À 1 ), alanine aminotransferase (121 IU l À 1 ), lactic dehydrogenase (3490 IU l À 1 ), ferritin (9769.7 ng ml À 1 ) and soluble interleukin-2 (IL-2) receptor (3230 U ml À 1 ). We could not find any known HLH genetic abnormality in the patient, but he fulfilled seven of the eight criteria for HLH. Serum levels of IL-6 and IL-8 had been already elevated in his cord blood, and serum levels of granulocyte-macrophage colony-stimulating factor and IL-8 were significantly increased on the second day of life. His symptoms regressed with the administration of hydrocortisone. We presumed that transplacental transfer of maternal antibodies could be related to the occurrence of HLH.
INTRODUCTION
Hemophagocytic lymphohistiocytosis (HLH) is caused by a prolonged and excessive activation of antigen-presenting cells and CD8 þ T cells, and encompasses several entities, including a primary familial HLH and a secondary form associated with infection, malignancies and rheumatologic disorders. 1 Suzuki et al. 2 reported only 20 neonatal cases during a 10-year period in Japan, and they did not find any neonatal patients with autoimmune-related secondary HLH.
We encountered a neonatal patient with HLH that may be caused by the transplacental transfer of maternal anti-Ro/SSA and anti-La/SSB antibodies. We determined the cytokine profile at several times in his clinical course.
CASE
Complete atrioventricular block was identified with fetal ultrasonography in a male patient at 29 weeks of gestation. The patient's heart rate was around 70 b.p.m. His mother did not show any signs or symptoms, but her serum was positive for anti-Ro/SSA (64 U ml À 1 ) and anti-La/SSB (32 U ml À 1 ) antibodies. She did not have any other auto-antibodies. The patient was born at 40 weeks of gestation by normal vaginal delivery, and his birth weight was 3292 g. His Apgar scores were 8 at both 1 and 5 min. His heart rate was around 70 b.p.m., but his general condition was fine. His platelet count was low (93.0 Â 10 3 ml
) and his serum level of C-reactive protein was negative at 0.02 mg dl À 1 . Serum levels of aspartate aminotransferase and alanine aminotransferase were 62 and 12 IU l ). Serum titers of anti-Ro/SSA and anti-La/SSB antibodies in the cord blood were positive (64 and 8 U ml À 1 , respectively). Immunoglobulin M was o5 mg dl À 1 and anti-cytomegalovirus immunoglobulin M antibody was negative in the cord blood. At 19 h after birth, his 
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platelet count had rapidly decreased to 51.0 Â 10 3 ml À 1 , and his C-reactive protein level had rapidly increased to 12.0 mg dl À 1 . His serum level of lactic dehydrogenase also increased to 974 IU l À 1 . At 22 h after the birth, he showed severe pulmonary hypertension and general hypotension. He received cardiopulmonary resuscitation, and then the continuous administration of isoprenaline and nitric oxide inhalation was started. His circulatory condition gradually improved, but he had elevated serum levels of aspartate aminotransferase (1027 IU l À 1 ), alanine aminotransferase (121 IU l À 1 ) and lactic dehydrogenase (3490 IU l À 1 ). At 32 h of life, he demonstrated elevated levels of ferritin (9769.7 ng ml À 1 ) and soluble interleukin-2 (IL-2) receptor (sCD25; 3230 U ml À 1 ). The patient's clinical and laboratory data and the criteria for HLH 3 are shown in Table 1 . No genetic abnormalities for PRF1 and normal expression levels of Munc 13-4/18-2 and Syntaxin 11 were found. We gave him a diagnosis of HLH and presumed that the HLH was related to the acute circulatory disturbance. Figure 1 shows the patient's clinical course. His circulatory condition and serum chemistry were improved by intravenous administration of hydrocortisone (2 mg kg À 1 every 6 h). We gradually tapered the dose of hydrocortisone and stopped the administration of hydrocortisone on day 24 of life, as shown in Figure 1 . The next day, however, his serum C-reactive protein was increased (7.46 mg dl ). His ferritin level was 1187.7 ng ml À 1
. We resumed the administration of hydrocortisone (1 mg kg À 1 every 6 h). At this point, the level of anti-Ro/SSA antibody was 8 U ml
, and the level of anti-La/SSB antibody was 1 U ml
. We more gradually tapered the dose of hydrocortisone and terminated the administration of hydrocortisone on day 85 after birth as shown in Figure 1 .
We measured serum cytokine levels, as described previously. 4 As shown in Table 2 , serum levels of IL-6 and IL-8 were elevated in the cord blood. On the second day of life, the most striking findings were the significantly elevated levels of Abbreviations: BW, birth weight; CB, cord blood; GA, gestational age; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN-g, interferon-g; IL, interleukin; MCP-1, monocyte chemotactic protein-1; MIP-1b, macrophage inhibitory protein-1b; PB, peripheral blood; TNF-a, tumor necrosis factor-a.
a Controls contained two groups. One group included 149 CB samples, and the other group included PB samples from eight newborn patients. The samples were collected from patients with various risk factors who were admitted to the Neonatal Intensive Care Unit of Jichi Medical University School of Medicine. The 149 CB samples were extracted from a group of 224 CB samples whose cytokine profiles were investigated in our previous paper. 4 The 75 samples of cases with premature rupture of membrane, chorioamnionitis and placental abruption were excluded. The other control group consisted of eight newborn patients with several minor risks consisting of slightly low birth weight (n ¼ 5), diabetic mothers (n ¼ 2) and hyperbilirubinemia caused by breast feeding (n ¼ 1). PB of controls was taken between the fourth and eighth days of life. Written informed consent was obtained from the controls' parents. Neonatal HLH with transfer of maternal auto-antibodies Y Suzuki et al serum granulocyte-macrophage colony-stimulating factor (342.7 pg ml À 1 ) and IL-8 (447.3 pg ml À 1 ). On the 18th day of life, when the patient's circulatory condition was stable, the serum levels of several cytokines were still high. On the 26th day of life, when the patient's serum C-reactive protein had increased after the initial attempt at hydrocortisone cessation, several cytokine levels were increased further, particularly interferon-g. On the 80th day of life, just before the successful termination of hydrocortisone administration, the serum levels of almost all cytokines were low ( Table 2 and Figure 1 ).
DISCUSSION
Macrophage activation syndrome is a special form of HLH that occurs in children and adults with autoimmune diseases. [5] [6] [7] [8] [9] [10] Imashuku et al.
7 studied 96 Japanese patients under 1 year of age with HLH, and they found that four patients (age range, 7 to 12 months) developed rheumatoid arthritis-associated macrophage activation syndrome. To the best of our knowledge, this report may be the first case of neonatal HLH caused by maternal transfer of antibodies.
Fukaya et al. 10 identified two adult patients with Sjö gren syndrome who had developed HLH in a group of 30 patients with autoimmune diseases. Neonatal lupus erythematosus is caused by the transplacental passage of maternal autoantibodies, most commonly anti-Ro/SSA and anti-La/SSB antibodies. Wisuthsarewong et al.
11 reported 17 patients with neonatal lupus erythematosus who were diagnosed at 28 to 84 days of life in Thailand. There has been no report of a neonatal patient with neonatal lupus erythematosus who developed HLH. Autoimmunerelated HLH is characterized by very high ferritin levels, severe cardiac impairment and responsiveness to corticosteroid. 9, 12 From these facts, it is plausible that anti-Ro/SSA and anti-La/SSB antibodies had a role in the development of HLH in this patient.
Patients with familial or secondary HLH have high serum levels of various pro-inflammatory cytokines such as interferon-g, IL-6, IL-8, IL-10, IL-12, IL-18 and tumor necrosis factor-a.
9, 13 We previously described a patient with familial HLH who developed hydrops fetalis.
14 This patient also had high levels of IL-6 and IL-8 in cord blood. Fetuses must avoid harmful inflammatory immune responses that could lead to preterm delivery; therefore, Th1 immune responses are usually depressed in utero. This fact may be related to the low levels of the other cytokines in cord blood. Several reports have identified interferon-g as the most important cytokine in the development of HLH. 9, 13 When corticosteroid therapy was reinitiated, our patient showed high levels of several cytokines including interferon-g. The immunological reaction at this time point might be different than the immunological reaction during the first hours of life.
This report may be the first report of a neonatal patient with autoimmune-related HLH. We think that it is important to accumulate information on neonatal patients with similar conditions to our patient in future studies to further elucidate the underlying mechanism.
